Piribedil

Piribedil

Clinical data
Routes of administration	Oral
ATC code	N04BC08 (WHO)
Pharmacokinetic data
Elimination half-life	1.7 – 6.9 hours
Excretion	Renal (68%) and biliary (25%)
Identifiers
IUPAC name 2-[4-(benzo[1,3]dioxol-5-ylmethyl)piperazin-1-yl]pyrimidine
CAS Number	3605-01-4
PubChem CID	4850
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H18N4O2
Molar mass	298.340 g/mol

WikiDoc Resources for Piribedil
Articles
Most recent articles on Piribedil Most cited articles on Piribedil Review articles on Piribedil Articles on Piribedil in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Piribedil Images of Piribedil Photos of Piribedil Podcasts & MP3s on Piribedil Videos on Piribedil
Evidence Based Medicine
Cochrane Collaboration on Piribedil Bandolier on Piribedil TRIP on Piribedil
Clinical Trials
Ongoing Trials on Piribedil at Clinical Trials.gov Trial results on Piribedil Clinical Trials on Piribedil at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Piribedil NICE Guidance on Piribedil NHS PRODIGY Guidance FDA on Piribedil CDC on Piribedil
Books
Books on Piribedil
News
Piribedil in the news Be alerted to news on Piribedil News trends on Piribedil
Commentary
Blogs on Piribedil
Definitions
Definitions of Piribedil
Patient Resources / Community
Patient resources on Piribedil Discussion groups on Piribedil Patient Handouts on Piribedil Directions to Hospitals Treating Piribedil Risk calculators and risk factors for Piribedil
Healthcare Provider Resources
Symptoms of Piribedil Causes & Risk Factors for Piribedil Diagnostic studies for Piribedil Treatment of Piribedil
Continuing Medical Education (CME)
CME Programs on Piribedil
International
Piribedil en Espanol Piribedil en Francais
Business
Piribedil in the Marketplace Patents on Piribedil
Experimental / Informatics
List of terms related to Piribedil

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Piribedil is a piperazine dopamine agonist; and marketed as TRIVASTAL Retard 50.

Trivastal retard 50 is also distributed as: Trastal, Trivastal 50 retard, Trivastal 50mg LP, Trivastan ritardo and Pronoran.

• Official site

Composition:

Piribedil 50 mg per tablet - sustained-release.

Indications:

- Treatment of Parkinson's disease, either as monotherapy (without L-dopa) or in combination with L-dopa therapy, in the early stages as well as in the advanced stages. - Treatment of pathological cognitive deficits in the elderly (impaired attention, memory, etc). Treatment of dizziness in the elderly. - Treatment of Retinal ischemic manifestations. Adjuvant treatment in intermittent claudication due to peripheral occlusive arterial disease of the lower limbs (stage 2). - (off label) anhedonia and treatment-resistant depression in unipolar and bipolar depressives

Dosage:

In Parkinson's disease: administration of Trivastal retard 50 should be initiated with 1 tablet daily during the first week. Dosage should then be gradually increased every week until achieving the optimal therapeutic dose: as monotherapy: 3 to 5 tablets in 3 to 5 divided doses daily. In combination with L-dopa therapy: 1 to 3 tablets daily. In other indications: 1 tablet daily at the end of the main meal. In severe cases: 2 tablets daily as 2 divided doses.

Trivastal retard 50 is a nonergot dopamine agonist, selective for D2 and D3 dopamine receptors subtypes at the cerebral and at the peripheral level.

Cardiogenic shock. Acute phase of myocardial infarction.

Adverse:

rare side effects: minor gastrointestinal disorders (nausea, vomiting, flatulence) in predisposed individuals, or when taken between meals. They may resolve with the following: individual dosage adjustment, and/or addition of domperidone. Orthostatic hypotension or drowsiness may occur, particularly in predisposed individuals (underlying condition or causative illness).

Dopaminergic antagonists.

Overdosage:

At very high doses, Trivastal retard 50 has an emetic action on the CTZ (chemoreceptive trigger zone). Tablets will thus be rapidly rejected, which explains why no data are currently available concerning the risk of overdosage.

Template:Drug-stub Template:Dopamine agonists